Announcements Trials

Browse Landscape

Phase

Status

Unknown 1 Not yet recruiting 1 Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neuroendocrine Tumors 4 Sarcoma 2 Neoplasms 2 Thyroid Neoplasms 1 Small Cell Lung Carcinoma 1 Sarcoma, Ewing 1 Rhabdomyosarcoma 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Osteosarcoma 1 Neuroectodermal Tumors, Primitive 1 Lymphoma 1 Cholangiocarcinoma 1 Carcinoid Tumor 1 Biliary Tract Neoplasms 1 Advanced Solid Tumors 1

Interventions

Gemcitabine 39 Cisplatin 24 Oxaliplatin 15 pembrolizumab 12 Capecitabine 12 Fluorouracil 9 Leucovorin 7 Albumin-Bound Paclitaxel 7 lenvatinib 6 Radiofrequency Ablation 6 Panitumumab 6 130-nm albumin-bound paclitaxel 6 Irinotecan 5 Bevacizumab 5 durvalumab 4 Taxes 4 Nivolumab 4 Hepatectomy 4 Drug Therapy 4 tremelimumab 3 apatinib 3 Radiosurgery 3 Platinum 3 Injections 3 Floxuridine 3 Cetuximab 3 1,2-diaminocyclohexaneplatinum II citrate 3 trametinib 2 spartalizumab 2 sintilimab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Cholangiocarcinoma × surufatinib × Clear all

NCT05236699 2025-02-14

CCGLC-005

Tongji Hospital

Phase 2 Completed

Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡